Liquidia Technologies Inc

Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The company was founded on June 28, 2020 and is headquartered in Morrisville, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Liquidia Technologies reports robust Q4 earnings, eyes YUTREPIA's market potential

Liquidia Technologies Inc (LQDA) showcased strong financial performance and promising prospects for its flagship product, YUTREPIA, in the pharmaceutical market. While facing challenges in legal proceedings and market competition, the company's focus on innovation, clinical trials, and strategic positioning bodes well for future growth and success.

Liquidia Technologies navigates legal hurdles to capitalize on YUTREPIA

Liquidia Technologies faces financial challenges with a net loss in Q1 2023 but holds a strong cash position. The success of YUTREPIA hinges on navigating legal hurdles and effectively differentiating itself in the market.

Liquidia Technologies reports solid Q2 results amidst legal victories

Liquidia Technologies Inc's Q2 2023 Earnings Call highlighted strong financials, legal victories, and strategic focus on R&D. While facing legal challenges and balancing expenses, the company remains confident in its progress. Opportunities in FDA approvals, clinical development, and strategic partnerships present avenues for growth.

Liquidia Technologies Inc (LQDA) reports strong progress and prepares for market expansion

Liquidia Technologies Inc (LQDA) made significant strides in developing inhaled treprostinil products, showcasing promising results and clear benefits.
While facing regulatory and market challenges, the company's strong commercial preparations and financial prudence position it well for future growth.
Opportunities in market expansion, successful product launches, and program development offer avenues for revenue growth and industry leadership.

Liquidia Technologies eyes FDA approval for YUTREPIA, targeting $3B market

Liquidia Technologies is poised for growth with a strong financial position and strategic focus on YUTREPIA to lead the treprostinil market.
While facing regulatory and operational challenges, the company's emphasis on addressing patient dosing effectively presents opportunities for market leadership.
The potential FDA approval of YUTREPIA post-March 31 opens doors to a $3 billion market opportunity, positioning the company for significant growth.

Liquidia Technologies reports strong Q1 performance and eyes market expansion

Liquidia Technologies Inc's Q1 2024 earnings call highlighted strong financial performance, market potential in inhaled treprostinil products, legal progress, and a focus on innovation. The company is well-positioned for commercial launch post-approval and aims to address the growing market demand for improved treatment options.

Liquidia Technologies reports Q2 results, eyes pulmonary hypertension market

Liquidia Technologies Inc reported mixed financial results for Q2 2024, with revenue of $3.7 million and a net loss.
The company's focus on YUTREPIA and L606 formulations presents promising opportunities in the pulmonary hypertension space.
Analyst inquiries highlighted key areas of interest, including product benefits, trial data, regulatory matters, and financial outlook.
With a strong cash position and ongoing FDA engagement, Liquidia is poised for potential growth and advancement in its pipeline.

Liquidia Technologies reports strong Q3 performance amidst regulatory challenges

Liquidia Technologies Inc's Q3 2024 Earnings Call highlighted strong financial performance, progress towards YUTREPIA approval, and strategic plans for product launch. Legal challenges and regulatory hurdles pose significant challenges, while opportunities for growth exist in product development and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. The company was founded on June 28, 2020, and is headquartered in Morrisville, NC.

Liquidia Technologies Inc. (LQDA) CEO Neal Fowler on Q2 2019 Results - Earnings Call Transcript

LQDA is up against United Therapeutics in the PAH market - but it claim its drug is better.

Liquidia Technologies: Targeting Pulmonary Arterial Hypertension Using Proprietary Drug Particle Generating Platform

Liquidia Technologies Inc. (LQDA) CEO Neal Fowler on Q1 2019 Results - Earnings Call Transcript

News for Liquidia Technologies Inc Stock (LQDA)